NASDAQ:TNXP - Tonix Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.90 -0.13 (-6.40 %)
(As of 05/24/2019 05:20 AM ET)
Previous Close$2.03
Today's Range$1.82 - $2.49
52-Week Range$1.55 - $51.10
Volume7.69 million shs
Average Volume1.19 million shs
Market Capitalization$11.57 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease. The company is also developing TNX-601 (tianeptine oxalate) as a daytime administration for the treatment of PTSD and potential indication -neurocognitive dysfunction associated with corticosteroid use that is in pre-investigational new drug (pre-IND) application stage; and TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus, which is in pre-IND application stage. Its product pipeline also includes TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

Receive TNXP News and Ratings via Email

Sign-up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TNXP
CUSIPN/A
Phone212-980-9155

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.93 per share

Profitability

Net Income$-26,090,000.00

Miscellaneous

Employees12
Market Cap$11.57 million
Next Earnings Date8/12/2019 (Estimated)
OptionableOptionable

Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work?

Shares of Tonix Pharmaceuticals reverse split on Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) released its quarterly earnings results on Monday, May, 13th. The company reported ($1.29) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.18) by $0.11. View Tonix Pharmaceuticals' Earnings History.

When is Tonix Pharmaceuticals' next earnings date?

Tonix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August 12th 2019. View Earnings Estimates for Tonix Pharmaceuticals.

What price target have analysts set for TNXP?

3 analysts have issued 1-year price objectives for Tonix Pharmaceuticals' stock. Their forecasts range from $4.00 to $80.00. On average, they anticipate Tonix Pharmaceuticals' stock price to reach $42.00 in the next year. This suggests a possible upside of 2,110.5% from the stock's current price. View Analyst Price Targets for Tonix Pharmaceuticals.

What is the consensus analysts' recommendation for Tonix Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tonix Pharmaceuticals.

Has Tonix Pharmaceuticals been receiving favorable news coverage?

News coverage about TNXP stock has been trending neutral recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tonix Pharmaceuticals earned a daily sentiment score of 0.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.

Who are some of Tonix Pharmaceuticals' key competitors?

What other stocks do shareholders of Tonix Pharmaceuticals own?

Who are Tonix Pharmaceuticals' key executives?

Tonix Pharmaceuticals' management team includes the folowing people:
  • Dr. Seth Lederman, Co-Founder, Pres, CEO & Chairman (Age 61)
  • Mr. Bradley Saenger, CFO & Treasurer (Age 45)
  • Dr. Gregory M. Sullivan, Chief Medical Officer & Sec. (Age 53)
  • Mrs. Jessica Edgar Morris, Chief Operating Officer
  • Dr. Ronald R. Notvest Ph.D., MBA, Exec. VP of Commercial Planning and Devel.

Who are Tonix Pharmaceuticals' major shareholders?

Tonix Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.70%), Dimensional Fund Advisors LP (0.26%) and Jane Street Group LLC (0.19%). Company insiders that own Tonix Pharmaceuticals stock include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals.

Which major investors are buying Tonix Pharmaceuticals stock?

TNXP stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP and Jane Street Group LLC. Company insiders that have bought Tonix Pharmaceuticals stock in the last two years include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Insider Buying and Selling for Tonix Pharmaceuticals.

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tonix Pharmaceuticals' stock price today?

One share of TNXP stock can currently be purchased for approximately $1.90.

How big of a company is Tonix Pharmaceuticals?

Tonix Pharmaceuticals has a market capitalization of $11.57 million. The company earns $-26,090,000.00 in net income (profit) each year or ($26.81) on an earnings per share basis. Tonix Pharmaceuticals employs 12 workers across the globe.

What is Tonix Pharmaceuticals' official website?

The official website for Tonix Pharmaceuticals is http://www.tonixpharma.com/.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]


MarketBeat Community Rating for Tonix Pharmaceuticals (NASDAQ TNXP)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  247 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  416
MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote "Outperform" if you believe TNXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/24/2019 by MarketBeat.com Staff

Featured Article: How mutual funds make money

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel